GlassScriptPhysician profile
James P Patyi
NPI 1548345630
$3,106.22
in general payments reported to CMS, 2019-2025
22 companies · $748 in 2025
The $748 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $260 · 2021: $445 · 2022: $498 · 2023: $383 · 2024: $513 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $455.44 | 2020-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Tarsus Pharmaceuticals, INC. | $391.40 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $337.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $287.52 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $271.84 | 2022-2025 | Xiidra, Miebo, Infuse |
| Aerie Pharmaceuticals, INC. | $198.50 | 2020-2021 | |
| Amgen INC. | $188.48 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $152.83 | 2019-2023 | |
| Sight Sciences, INC. | $119.26 | 2024-2025 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $111.43 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $106.06 | 2022-2025 | Tyrvaya |
| Rxsight INC | $95.91 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Horizon Therapeutics Plc | $79.58 | 2020-2023 | Tepezza |
| Allergan, INC. | $61.92 | 2021-2022 | |
| Harrow Eye, LLC | $44.77 | 2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $43.41 | 2022-2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $41.74 | 2019-2021 | |
| Glaukos Corporation | $35.33 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Genentech USA, INC. | $25.59 | 2023 | Vabysmo |
| Dompe US, INC. | $20.21 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $18.92 | 2020 | |
| Shire North American Group INC | $18.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Patyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.